Modified human IGF-IR antibodies
US7371378B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2004 |
| Grant date | May 13, 2008 |
| Priority date | — |
| Expiry date | Feb 14, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/567
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germlne framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.